Machine signal
Active cluster sell — 6 distinct insiders, $15.9M, window ends Sep 28, 2026.
Figures computed from official regulatory filings — .
Analysttarget 109.9 USD (+68%) · consensus 4.5/5 · 20 buy · 2 hold · 0 sell
Ownershipinsiders 0.65% · institutions 125.99% · short 19.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CYTOKINETICS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
51 buys1,446 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Blum Robert I | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blum Robert I | Exercise | $79.5K | SEC |
| Blum Robert I | Sell | $490.9K | SEC |
| Malik Fady Ibraham | Exercise | $27.3K | SEC |
| Malik Fady Ibraham | Sell | $239K | SEC |
| Malik Fady Ibraham | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blum Robert I | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blum Robert I | Exercise | $79.5K | SEC |
| Blum Robert I | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blum Robert I | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blum Robert I | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blum Robert I | Sell | $6.8M | Unusual size | SEC |
| Blum Robert I | Sell | $550.8K | SEC |
| Landry Robert E | Sell | $72.1K | SEC |
| Landry Robert E | Sell | $74.7K | SEC |
| Malik Fady Ibraham | Exercise | $27.3K | SEC |
| Malik Fady Ibraham | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Malik Fady Ibraham | Sell | $264.1K | SEC |
| PARSHALL B LYNNE | Sell | $357.4K | SEC |
| Blum Robert I | Sell | $526.8K | SEC |
| Callos Andrew | Exercise | $232.6K | SEC |
| Callos Andrew | Sell | $702.4K | SEC |
| Callos Andrew | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blum Robert I | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Blum Robert I | Exercise | $79.5K | SEC |